Xbrane Biopharma AB (publ)

OM:XBRANE Stock Report

Market Cap: SEK 238.6m

Xbrane Biopharma Valuation

Is XBRANE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of XBRANE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate XBRANE's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate XBRANE's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for XBRANE?

Key metric: As XBRANE is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for XBRANE. This is calculated by dividing XBRANE's market cap by their current revenue.
What is XBRANE's PS Ratio?
PS Ratio1.2x
SalesSEK 199.81m
Market CapSEK 238.60m

Price to Sales Ratio vs Peers

How does XBRANE's PS Ratio compare to its peers?

The above table shows the PS ratio for XBRANE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average27.2x
VIVE Vivesto
22.9x-118.4%SEK 151.2m
IMMU Mendus
61.4x89.9%SEK 426.1m
ATORX Alligator Bioscience
7.3x-8.0%SEK 202.0m
NXTCL NextCell Pharma
17.2xn/aSEK 194.4m
XBRANE Xbrane Biopharma
1.2x61.1%SEK 238.6m

Price-To-Sales vs Peers: XBRANE is good value based on its Price-To-Sales Ratio (1.2x) compared to the peer average (27.2x).

Price to Sales Ratio vs Industry

How does XBRANE's PS Ratio compare vs other companies in the SE Biotechs Industry?

8 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.12.0x20.8%
XBRANE Xbrane Biopharma
 1.2x61.1%US$21.64m
SPRINT Sprint Bioscience
1.8x27.6%US$10.26m
GEAN Genetic Analysis
1.2xn/aUS$2.14m
XBRANE 1.2xIndustry Avg. 12.0xNo. of Companies8PS01224364860+
8 CompaniesEstimated GrowthMarket Cap
Industry Avg.12.0x44.6%
XBRANE Xbrane Biopharma
 1.2x130.2%US$21.64m
No more companies

Price-To-Sales vs Industry: XBRANE is good value based on its Price-To-Sales Ratio (1.2x) compared to the Swedish Biotechs industry average (12x).

Price to Sales Ratio vs Fair Ratio

What is XBRANE's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

XBRANE PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.2x
Fair PS Ratio18.3x

Price-To-Sales vs Fair Ratio: XBRANE is good value based on its Price-To-Sales Ratio (1.2x) compared to the estimated Fair Price-To-Sales Ratio (18.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst XBRANE forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 0.16
SEK 0.45
+188.5%
33.3%SEK 0.60SEK 0.30n/a2
Dec ’25SEK 0.18
SEK 0.45
+143.2%
33.3%SEK 0.60SEK 0.30n/a2
Nov ’25SEK 0.23
SEK 0.45
+99.1%
33.3%SEK 0.60SEK 0.30n/a2
Oct ’25SEK 0.18
SEK 0.45
+145.4%
33.3%SEK 0.60SEK 0.30n/a2
Sep ’25SEK 0.15
SEK 0.45
+202.0%
33.3%SEK 0.60SEK 0.30n/a2
Aug ’25SEK 0.18
SEK 0.60
+226.8%
8.3%SEK 0.65SEK 0.55n/a2
Jul ’25SEK 0.25
SEK 0.60
+136.2%
8.3%SEK 0.65SEK 0.55n/a2
Jun ’25SEK 0.30
SEK 0.60
+101.3%
8.3%SEK 0.65SEK 0.55n/a2
May ’25SEK 0.22
SEK 0.63
+188.7%
4.0%SEK 0.65SEK 0.60n/a2
Mar ’25SEK 0.68
SEK 61.38
+8,925.7%
98.8%SEK 122.00SEK 0.75n/a2
Feb ’25SEK 1.61
SEK 84.00
+5,117.4%
45.2%SEK 122.00SEK 46.00n/a2
Jan ’25SEK 10.00
SEK 84.00
+740.0%
45.2%SEK 122.00SEK 46.00n/a2
Dec ’24SEK 7.51
SEK 116.00
+1,444.6%
5.2%SEK 122.00SEK 110.00SEK 0.182
Nov ’24SEK 22.70
SEK 116.00
+411.0%
5.2%SEK 122.00SEK 110.00SEK 0.232
Oct ’24SEK 27.20
SEK 116.00
+326.5%
5.2%SEK 122.00SEK 110.00SEK 0.182
Sep ’24SEK 34.65
SEK 116.00
+234.8%
5.2%SEK 122.00SEK 110.00SEK 0.152
Jul ’24SEK 77.20
SEK 217.50
+181.7%
26.4%SEK 275.00SEK 160.00SEK 0.252
Jun ’24SEK 80.60
SEK 224.00
+177.9%
22.8%SEK 275.00SEK 173.00SEK 0.302
May ’24SEK 93.20
SEK 224.00
+140.3%
22.8%SEK 275.00SEK 173.00SEK 0.222
Apr ’24SEK 85.90
SEK 224.00
+160.8%
22.8%SEK 275.00SEK 173.00SEK 0.302
Mar ’24SEK 83.70
SEK 224.00
+167.6%
22.8%SEK 275.00SEK 173.00SEK 0.682
Feb ’24SEK 101.80
SEK 224.00
+120.0%
22.8%SEK 275.00SEK 173.00SEK 1.612
Jan ’24SEK 82.10
SEK 224.00
+172.8%
22.8%SEK 275.00SEK 173.00SEK 10.002

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 11:48
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Xbrane Biopharma AB (publ) is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John SavinEdison Investment Research
Hans MählerNordea Markets
null nullNordea Markets